Arvinas, Inc. ARVN
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Arvinas, Inc. (ARVN) is a healthcare company listed in the US with a market value of about $447M. In the twelve months to September 30, 2026 it had revenue of $275M and net income of -$10M, a net margin of -3.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 59% a year, a 5-year average ROIC of -33%.
About Arvinas
Arvinas is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $8M in 2017 to $263M in 2025, growth of about 55.8% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 33% over three years (dilution for shareholders). It spends 109% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $275M | $263M | $263M | $78M | $131M | $54M | $26M | $43M | $14M | $8M |
| Net income | -$10M | -$81M | -$199M | -$367M | -$282M | -$191M | -$119M | -$70M | -$41M | -$24M |
| Free cash flow | -$160M | -$276M | -$261M | -$351M | -$280M | $555M | -$96M | -$47M | -$19M | $4M |
| EPS (diluted) | $-0.10 | $-1.14 | $-2.77 | $-6.62 | $-5.31 | $-3.82 | $-3.02 | $-2.13 | $-25.45 | $-15.08 |
| Net margin | -3.5% | -30.8% | -75.5% | -467.9% | -215.0% | -356.3% | -460.6% | -163.5% | -289.6% | -317.3% |
| ROIC | — | -21.1% | -34.6% | -47.8% | -36.4% | -23.9% | -18.7% | -17.6% | -24.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $14.00, 105% above the current price; targets range from $8.00 to $21.00; the consensus rating is “Buy”; expected EPS is $0.16 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Arvinas pay a dividend?
Not currently.
Is Arvinas a good stock to buy?
We do not give buy or sell advice. Arvinas scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.